These include <i>CRLF2</i> and <i>PAX5</i> alterations<i>, TP53, CREBBP</i> and <i>ERG</i> mutations, characteristic genetic aberrations in BCR-ABL1-like B-ALL and others.
Our data suggest the introduction of a novel WHO entity within the B lymphoblastic leukemia/lymphoma group showing low hypodiploid/very low tetraploid karyotype and concomitant TP53 mutation.